CLINICAL_TRIALS
trial_result
· 2022-05-26
Clinical Trial Update: Evaluation of the Efficacy and Safety of VX-864 in Subjects With the PiZZ Genotype [Phase 2]
Summary
Phase 2 trial evaluating VX-864 for Alpha1-Antitrypsin Deficiency has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Alpha1-Antitrypsin Deficiency | Phase 2 | Status: COMPLETED | Results posted: 2022-05-26